Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05517811 | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection(TEG) | recruiting | — | 200 | University of Colorado, DenverOTHER | 1 | Aug 24, 2026 |
| clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07781176 | Different Acupoint Stimulation for Postoperative Gastrointestinal Dysfunction in Primary Liver Cancer Patients | not yet recruiting | N/A | 132 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07782632 | Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma | recruiting | — | 467 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT03655002 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT04410302 | Patient-Derived Xenografts to Reduce Cancer Health Disparities | recruiting | — | 500 | University of California, DavisOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06166576 | Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis(RESOLVE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06178198 | Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma(RESCUE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06453590 | Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents | active not recruiting | N/A | 450 | Region StockholmOTHER_GOV | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06773845 | Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria(BEAT-UT7) | recruiting | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07608458 | Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy | not yet recruiting | N/A | 70 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma(AB-TCZ) | not yet recruiting | Phase 2 | 51 | CHA UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT06944483 | Same-day Radioembolization for Large HCC(ISTAR-01) | recruiting | — | 138 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06979219 | Streamlining Radioembolization for Small HCC(ISTAR-02) | recruiting | — | 146 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07043387 | Streamlining Radioembolization for CCC and Metastatic Liver Cancer(ISTAR-03) | recruiting | — | 60 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07727759 | CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure(BEYOND-SIZE) | recruiting | — | 1,070 | Minia UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04891289 | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | recruiting | Phase 2 | 164 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06048133 | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | active not recruiting | Phase 2 | 33 | Nataliya UbohaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07070362 | Digital Early Warning System for Acute Lung Injury in Liver Surgery | recruiting | — | 3,000 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | recruiting | Phase 3 | 226 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07209813 | GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 48 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07767994 | AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer(ICORE-GBC) | not yet recruiting | Phase 2 | 22 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07768085 | Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT | not yet recruiting | N/A | 40,000 | Shengjing HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2) | active not recruiting | Phase 3 | 908 | AstraZenecaINDUSTRY | 24 | Aug 14, 2026 | clinicaltrials |
| NCT04221893 | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | recruiting | N/A | 28 | University of California, San FranciscoOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04550481 | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | active not recruiting | Phase 2 | 35 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764835 | Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)(Screening HCC) | not yet recruiting | — | 300 | D'Or Institute for Research and EducationOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07765433 | Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 / Phase 3 | 336 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Aug 14, 2026 | clinicaltrials |
| NCT05211323 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05701488 | SIRT With Tremelimumab and Durvalumab for Resectable HCC | active not recruiting | Phase 1 | 20 | Jiping Wang, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06618300 | Streamlined Resin Y90 Radiation Segmentectomy for Small HCC(One&Done) | active not recruiting | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT07053072 | PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma. | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2026source: clinicaltrials